Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Catherine Beauchemin"'
Autor:
Fares Antaki, Imane Hammana, Marie-Catherine Tessier, Andrée Boucher, Maud Laurence David Jetté, Catherine Beauchemin, Karim Hammamji, Ariel Yuhan Ong, Marc-André Rhéaume, Danny Gauthier, Mona Harissi-Dagher, Pearse A Keane, Alfons Pomp
Publikováno v:
JMIR Diabetes, Vol 9, p e59867 (2024)
BackgroundDiabetic retinopathy (DR) affects about 25% of people with diabetes in Canada. Early detection of DR is essential for preventing vision loss. ObjectiveWe evaluated the real-world performance of an artificial intelligence (AI) system that a
Externí odkaz:
https://doaj.org/article/41c2522e11004aca9e05b4b7aa1b5eea
Autor:
Jean Lachaine, Catherine Beauchemin, Kimberly Guinan, Philippe Thebault, Andrew Aw, Versha Banerji, Isabelle Fleury, Carolyn Owen
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 332-345 (2021)
Background: Continuous oral targeted therapy (OTT) for chronic lymphocytic leukemia (CLL) represents an effective therapy but also a major economic burden on the healthcare system. This study aimed to estimate future direct costs, along with the prev
Externí odkaz:
https://doaj.org/article/4cb8792bbcc348f8a927618a83a11e85
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2018 (2018)
Objective. The objective of this literature review was to evaluate the existing evidence regarding the cost-effectiveness of treatment options in IBD. Methods. A systematic review of the literature was conducted to identify economic evaluations of IB
Externí odkaz:
https://doaj.org/article/113f3b816f254410a8a857dafdf2d1d1
Autor:
Martin Barbeau, Paul Harasymowycz, Catherine Royer, Katherine Jobin-Gervais, Jean Lachaine, Amy Xianying Cui, Catherine Beauchemin, K. Mathurin
Publikováno v:
British Journal of Ophthalmology. 106:640-647
Background/aimsTo assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP).MethodsA systematic lit
Autor:
Yves Poulin, Fei Fei Liu, Catherine Beauchemin, Anne-Julie Gaudreau, Clarabella Yim, Jean Lachaine, Catherine Royer
Publikováno v:
Journal of Cutaneous Medicine and Surgery. 24:573-587
Background In Québec, targeted biologic therapies for moderate to severe plaque psoriasis are restricted to patients who have not responded to phototherapy or conventional systemic treatment, primarily due to high drug costs. Apremilast, an oral tre
Autor:
Joëlle Bibeau, Erin Hillhouse, Catherine Beauchemin, K. Mathurin, Yasmine Rahal, Jean Lachaine, Diana Parison
Publikováno v:
Advances in Therapy
Introduction To save costs to the healthcare system, forced non-medical switch (NMS) policies that cut drug coverage for originator biologics and fund only less expensive biosimilars are being implemented. However, costs related to the impact of NMS
Autor:
Jeanne-Marie Giard, Damien Olivié, Milena Cerny, Boyan Fan, Joshua Bérubé, Catherine Beauchemin, An Tang, Paulo Henrique Lima
Publikováno v:
American Journal of Roentgenology. 213:17-25
OBJECTIVE. The purpose of this study is to compare imaging-based surveillance and diagnostic strategies in patients at risk for hepatocellular carcinoma (HCC) while taking into account technically inadequate examinations and patient compliance. MATER
Autor:
Julie Patenaude, Jean Lachaine, Joanna Bougie, Pratap Chokka, Joëlle Bibeau, Catherine Beauchemin, Jean Proulx
Publikováno v:
CNS Spectrums. 25:372-379
Objective.The AtWoRC study is an interventional, open-label Canadian study that demonstrated significant improvements in cognitive function and workplace productivity in patients with major depressive disorder (MDD) treated with vortioxetine for a cu
Autor:
Philippe Thebault, Isabelle Fleury, Andrew Aw, Jean Lachaine, Catherine Beauchemin, Versha Banerji, Carolyn Owen, K. Guinan
Publikováno v:
Current Oncology
Volume 28
Issue 1
Pages 37-345
Current Oncology, Vol 28, Iss 37, Pp 332-345 (2021)
Volume 28
Issue 1
Pages 37-345
Current Oncology, Vol 28, Iss 37, Pp 332-345 (2021)
Background: Continuous oral targeted therapy (OTT) for chronic lymphocytic leukemia (CLL) represents an effective therapy but also a major economic burden on the healthcare system. This study aimed to estimate future direct costs, along with the prev
Publikováno v:
Value in Health. 24:S15-S16